Mumbai: Sun Pharmaceutical who is the India’s largest drug maker is obtained approval from the US FDA to Generic Copies of Gleevec. After the Sun, various experts are planning to stars the drug making.
After a long time, Sun Pharmaceutical which is India’s largest drug maker proclaimed that it was received approval from the US FDA for generic copies of Gleevec, a drug that treats chronic myeloid leukemia, a rare form of blood cancer.
Sun said that it was permitted for beginning its versions of Gleevec of 1st Feb 2016. Sun Pharma stock was jumped 4% to Rs. 756/- on news of the approval at 11.20 on Friday. Novartis has patented of Gleevec and yearly sale of $2.5 billion in the U.S.
“We received one of the subsidiaries of final approval for 400 mg and 100 mg tablets” added Sun. Analysts have been informed by Sun Pharma management that Gleevec product was shifted by it filing from Halol and the manufacturing site is presently undergoing curative actions on directions from the US FDA.
Professionals added that Sun may obtain an extra sale of around $250 million at the time of its 6-month separate period. After this Sun Pharma, few other Indian drug makers containing Dr. Reddy expected for launching the drug.
13 total views, 1 views today